Predictors of anemia associated with pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C

碩士 === 中國醫藥大學 === 臨床醫學研究所碩士班 === 99 === Background and Aims: The current treatment of choice for chronic hepatitis C is the combination of pegylated interferon and ribavirin. One major side effect of combination antiviral therapy is anemia that will influence life quality and usually needs dose redu...

Full description

Bibliographic Details
Main Authors: Ta-Wei Chen, 陳達位
Other Authors: 彭成元
Format: Others
Language:zh-TW
Published: 2011
Online Access:http://ndltd.ncl.edu.tw/handle/22079445753437626076